Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA seeks data on BPA-containing devices

This article was originally published in The Gray Sheet

Executive Summary

FDA is requesting information on devices and other medical products that contain the chemical Bisphenol A, whether as part of the product or its packaging, the agency announces Oct. 15. NIH's National Toxicology Program released a draft report in April, finalized Sept. 3, on the potential for BPA to leach from plastics in consumer products and some medical products. After convening an agency-wide taskforce, FDA released a draft assessment Aug. 15 downplaying the toxicity and health risks of BPA in food-contact applications only (1"The Gray Sheet" Aug. 18, 2008, In Brief). But Congressional leaders are investigating a potential conflict of interest because Dr. Martin Philbert, chair of FDA's BPA advisory panel, heads a research center that received a $5 million donation from retired medical equipment manufacturer Charles Gelman, who advocates BPA's safety. Comments on the presence and risks of BPA in devices and other medical products are due Dec. 29

You may also be interested in...



Test Methods Needed To Understand Safety Risks Of Bisphenol A In Devices

AdvaMed is urging a "methodical, scientific" approach to assessing the use of bisphenol A in medical devices, in the face of public concerns that the leachable chemical could pose health risks

FDA on bisphenol A

Agency's decision to restrict its initial toxicity analysis of bisphenol A (BPA) to food-contact applications such as infant formula packaging "severely limits the usefulness" of the agency's draft 1assessment issued in August, says a subcommittee to FDA's Science Board in a 2report posted online Oct. 29. The report says FDA should have considered the "totality of exposures," including from medical devices used in the neonatal intensive care unit, to guide more accurate calculations. The observation is one of several critiques lodged at FDA's assessment, which the subcommittee says overlooks potentially informative data and comes to questionable conclusions about the safety margins for BPA levels in food packaging. FDA has said it plans to develop a separate assessment of BPA in medical products (3"The Gray Sheet" Oct. 20, 2008, In Brief). The subcommittee presented the report at an Oct. 31 Science Board meeting

FDA splits up BPA report

FDA released a draft assessment Aug. 15 downplaying the toxicity and health risks of the chemical bisphenol A (BPA) in food-contact applications, such as baby bottles and drink containers, and will issue a separate report focused on medical products at a later date, the agency says. NIH's National Toxicology Program released a report in April on the potential for BPA to leach from plastics in consumer products and some medical products (1"The Gray Sheet" May 12, 2008, p. 6). The BPA subcommittee of FDA's science board will meet Sept. 16 to discuss the food-related report

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel